SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 8th, 2017 • Cancer Genetics, Inc • Services-medical laboratories • New York
Contract Type FiledDecember 8th, 2017 Company Industry JurisdictionThis Securities Purchase Agreement (this “Agreement”) is dated as of December 8, 2017, between Cancer Genetics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
COMMON STOCK PURCHASE WARRANT CANCER GENETICS, INC.Common Stock Purchase Warrant • December 8th, 2017 • Cancer Genetics, Inc • Services-medical laboratories
Contract Type FiledDecember 8th, 2017 Company IndustryTHIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after six months following the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on June , 2019(1) (the “Termination Date”) but not thereafter, to subscribe for and purchase from Cancer Genetics, Inc., a Delaware corporation (the “Company”), up to shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s common stock (the “Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
STRICTLY CONFIDENTIAL Cancer Genetics, Inc.Exclusive Agency Agreement • December 8th, 2017 • Cancer Genetics, Inc • Services-medical laboratories • New York
Contract Type FiledDecember 8th, 2017 Company Industry Jurisdiction